PER-075-10已完成未知
A 5-YEAR OPEN LABEL EXTENSION TO: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF ODANACATIB (MK-0822) IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
MERCK SHARP & DOHME PERU S.R.L.,0 个研究点目标入组 3 人开始时间: 2010年11月10日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 55 至 80（—）
- 性别
- Female
入选标准
- •The patient has met all the initial inclusion criteria and has not met any of the exclusion criteria of Protocol 004-22. Note: There is no specific BMD T score required for eligibility in this extension study on Visit 27 (Month 60) or on Visit 27E. Patients who meet the criteria for excessive bone loss should be discontinued on Visit 27 (see Section 3.2.5.6 for details).
- •The patient has participated and has completed 60 months of treatment in Protocols 004-2, 004-11 and 004-22 (which will be determined in Visit 27 / Month 60),
- •The patient generally has good health, according to medical history, physical examination and laboratory evaluation.
排除标准
- •The patient has withdrawn from Protocol 004-22 for any reason before completing 60 months of treatment.
- •The patient experienced a fracture in the hip, spine or other fragility fracture during previous studies (004-02, 004-11 and 004-22) and would prefer to receive another therapy for osteoporosis (bisphosphonates or PTH) for which She is eligible.
- •The patient was diagnosed with a primary parathyroid disease during the previous studies (004-02, 004-11 and 004-22) and has an elevated PTH or serum calcium level greater than the upper limit of the normal range.
- •The patient has hypocalcemia, which is defined as a serum calcium level <8.5 mg / dL, when corrected for albumin, or shows evidence of secondary hyperparathyroidism.
- •The patient has significant clinical or laboratory abnormalities at the baseline of this extension study (Visit 27 / .Mcs 60) which, in the opinion of the researcher, could complicate the interpretation of the study results or represent an additional risk for patient (for example, hospitalized patients should be excluded for this reason).
- •The patient has cancer or presented a diagnosis of any malignancy during previous studies (004-02, 004-11 and 004-22), except for basal cell or squamous cell skin cancer or cervical cancer treated in situ adequately.
- •The patient is taking> 10,000 lU daily of Vitamin A (with the exception of beta carotene) or> 5,000 lU daily of Vitamin D.
- •The patient has received a treatment that could have an effect on the bone, which includes, without limitation: a) Current use of chemotherapy or heparin. b) Protease inhibitors for the treatment of HIV at any time. c) The patient is taking an anticonvulsant, and calcium metabolism rates are not within normal limits (Note: if serum calcium is within normal limits, the patient can enroll based on this criterion) .
- •Current use of systemic azole antifungals (eg, ketoconazole, fluconazole, itraconazole, miconazole, posaconozole, ravuconazole and systemic voriconazole) and other strong CYP3A4 inhibitors, such as clarithromycin and telithromycin (note: azithromycin is allowed)
- •The patient is currently receiving treatment with strong inducers of CYP3A4 (for example, rifampin [rifampicin], phenobarbital, barbiturates, carbamazepine, phenytoin, St. John´s wort, nevirapine, efavirenz and etravirine).
- •The patient is, in the opinion of the investigator, legally incompetent or mentally disabled, so that informed consent cannot be obtained, or the patient cannot read or cannot understand written material.
- •The patient has participated in a study with an investigational drug other than Protocol 004-22 within the last 30 days.
- •The patient currently uses recreational or illegal drugs, or has had a recent history of drug addiction or alcoholism or drug or alcohol dependence.
- •The patient demonstrates failure to follow the procedures required in the study.
研究者
相似试验
进行中（未招募）
不适用
A 5-Year Open Label Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in the Treatment of Postmenopausal Women with Osteoporosis - Cat-K II b Osteoporosis StudyPostmenopausal OsteoporosisMedDRA version: 14.1Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2005-001511-22-DKMerck Sharp & Dohme Corp.90
进行中（未招募）
不适用
A Study to Assess the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) vs placebo in the Treatment of Women With OsteoporosisMedDRA version: 17.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal OsteoporosisEUCTR2005-001511-22-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,375
进行中（未招募）
1 期
/APostmenopausal OsteoporosisMedDRA version: 18.1 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2007-002693-66-BGMerck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc.16,071
进行中（未招募）
1 期
An Open-Label 5-Year 2nd Extension for 5 years to: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and CalciumMedDRA version: 19.0 Level: PT Classification code 10031285 Term: Osteoporosis postmenopausal System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersPostmenopausal OsteoporosisEUCTR2007-002693-66-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., U.S.A.16,071
进行中（未招募）
1 期
A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and CalciumPostmenopausal OsteoporosisEUCTR2011-005514-10-LTMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.8,254